Outlook Therapeutics Limited secures contract for Pharmaceutical Products - Agreement in accordance with Section 130a (8) SGB V I V M * 130c Paragraph 1 SGB V for the active ingredient Bevacizumab Gamma (Lytenava (TM) )

Posted On: 2025-05-22

Germany, May 22 -- Germany based Outlook Therapeutics Limited has secured contract from AOK Baden-Wurttemberg for Pharmaceutical Products - Agreement in accordance with Section 130a (8) SGB V I V M * 130c Paragraph 1 SGB V for the active ingredient Bevacizumab Gamma (Lytenava (TM) ). The value of the contract is worth 22100000 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Outlook Therapeutics Limited secures contract for Pharmaceutical Products - Agreement in accordance with Section 130a (8) SGB V I V M * 130c Paragraph 1 SGB V for the active ingredient Bevacizumab Gamma (Lytenava (TM) )